NFL BIOSCIENCES: 2023 half-year financial and business report
NFL Biosciences: 2023 half-year financial and business report Admission on Euronext Growth Paris: €5m raised from institutional, historical, and individual investors (July 2023) CESTO II Phase II/III clinical trial approved in Australia (May 2023) and France (September 2023) Clinical team…